Yiyang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiyang Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Guilin Yu
Department of Clinical Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning, China
2 shared publications- Guohua Zhao
College of Food Science, Southwest University, Chongqing 400715, People's Republic of China; Chongqing Key Laboratory of Speciality Food Co-Built by Sichuan and Chongqing, Chongqing 400715, People's Republic of China; College of Life Science, Sichuan Normal University, Chengdu 610101, People's Republic of China
2 shared publications Jinnian Ge
Department of Clinical Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning, China
2 shared publications- Longfei Xie
ENN Group Co.,Ltd., Langfang, China
2 shared publications - Qingyu Ji
Department of Radiology, The Second Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, 014030, China
2 shared publications Aiming Xu
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- 13 August 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (2) , 1379-1394
Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study
Proliferation marker Ki-67 and immune checkpoint Programmed Cell Death Ligand 1 (PD-L1) are both proteins associated with tumor treatment response. To develop and validate two dynamic nomograms from dual-energy CT (DECT) for noninvasive evaluation of the expression status of these two proteins in advanced gastric cancer (AGC), and explore their associations with treatment response. In this multicenter prospective and retrospective study, eligible AGC participants who underwent DECT scans were recruited into two study groups (Ki-67 and PD-L1 groups), with their clinical and DECT characteristics collected and measured. The prediction models (Ki-67 dynamic nomogram (KIDN) and PD-L1 dynamic nomogram (PDDN)) were constructed by logistic regression classifier, respectively, and two online calculators were established based on models. The performance of nomograms was comprehensively evaluated. In total, 459 and 417 eligible patients were analyzed in the Ki-67 and PD-L1 groups, respectively. The nomograms discriminating Ki-67 and PD-L1 achieved AUCs of 0.755 and 0.726, respectively, in the external validation cohort. Additionally, the two nomograms significantly or slightly outperformed any single predictor in both the training and validation cohorts. In both cohorts, KIDN and PDDN showed favorable calibration (Hosmer-Lemeshow test, all p < 0.05) and clinical utility confirmed by decision curve analysis. Moreover, they demonstrated prognostic performance consistent with actual biomarkers and were associated with clinical response to immuno-chemotherapy (both p < 0.05). The dynamic nomograms, which integrate clinical features and DECT quantitative parameters, enable noninvasive evaluation of treatment-related protein expression in AGC. Question Noninvasive tools for accurately evaluating Ki-67 and PD-L1 expression status in advanced gastric cancer (AGC) are currently inadequate. Findings Dual-energy CT-based nomograms demonstrated favorable performance in evaluating Ki-67 and PD-L1 expression status and were associated with response to immuno-chemotherapy in AGC. Clinical relevance We developed online calculators based on prediction models that may serve as a supplement to current invasive methods (e.g., immunohistochemistry), potentially aiding therapeutic decision-making.
- 13 August 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (2) , 1379-1394
Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study
Proliferation marker Ki-67 and immune checkpoint Programmed Cell Death Ligand 1 (PD-L1) are both proteins associated with tumor treatment response. To develop and validate two dynamic nomograms from dual-energy CT (DECT) for noninvasive evaluation of the expression status of these two proteins in advanced gastric cancer (AGC), and explore their associations with treatment response. In this multicenter prospective and retrospective study, eligible AGC participants who underwent DECT scans were recruited into two study groups (Ki-67 and PD-L1 groups), with their clinical and DECT characteristics collected and measured. The prediction models (Ki-67 dynamic nomogram (KIDN) and PD-L1 dynamic nomogram (PDDN)) were constructed by logistic regression classifier, respectively, and two online calculators were established based on models. The performance of nomograms was comprehensively evaluated. In total, 459 and 417 eligible patients were analyzed in the Ki-67 and PD-L1 groups, respectively. The nomograms discriminating Ki-67 and PD-L1 achieved AUCs of 0.755 and 0.726, respectively, in the external validation cohort. Additionally, the two nomograms significantly or slightly outperformed any single predictor in both the training and validation cohorts. In both cohorts, KIDN and PDDN showed favorable calibration (Hosmer-Lemeshow test, all p < 0.05) and clinical utility confirmed by decision curve analysis. Moreover, they demonstrated prognostic performance consistent with actual biomarkers and were associated with clinical response to immuno-chemotherapy (both p < 0.05). The dynamic nomograms, which integrate clinical features and DECT quantitative parameters, enable noninvasive evaluation of treatment-related protein expression in AGC. Question Noninvasive tools for accurately evaluating Ki-67 and PD-L1 expression status in advanced gastric cancer (AGC) are currently inadequate. Findings Dual-energy CT-based nomograms demonstrated favorable performance in evaluating Ki-67 and PD-L1 expression status and were associated with response to immuno-chemotherapy in AGC. Clinical relevance We developed online calculators based on prediction models that may serve as a supplement to current invasive methods (e.g., immunohistochemistry), potentially aiding therapeutic decision-making.
- Open Access
- 30 September 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
N6-Methyladenosine Modification of PTTG3P Contributes to Colorectal Cancer Proliferation via YAP1
Background: Long noncoding RNAs (lncRNAs) have emerged to have irreplaceable roles in the epigenetic regulation of cancer progression, but their biological functions in colorectal cancer (CRC) remain unclear. Methods: LncRNA expression profiles in CRC tissue and their normal counterpart were explored. Through gain and loss of function approaches, the role of lncRNA PTTG3P was validated in relevant CRC cells and subcutaneous tumor model. The correlations of PTTG3P expression with clinical outcomes were assessed. Results: PTTG3P was upregulated in CRC tissues and was closely correlated with unsatisfactory prognosis. PTTG3P facilitated glycolysis and proliferation, and the transcriptional regulator YAP1 was necessary for PTTG3P-induced proliferation. Mechanistically, the N6-methyladenosine (m6A) subunit METTL3 increased PTTG3P expression by influencing its stability, while insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) could identify PTTG3P m6A methylation status and bind to it. IGF2BP2 knockdown partly recovered PTTG3P expression induced by METTL3, indicating that METTL3-regulated PTTG3P expression depended on the presence of IGF2BP2. Finally, rescue assays validated the critical role of the METTL3/PTTG3P/YAP1 axis on CRC proliferation. Conclusions: PTTG3P is an independent prognostic biomarker for CRC. The METTL3/PTTG3P/YAP1 axis promotes the progression of CRC and is a promising treatment target.
- 30 September 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessN6-Methyladenosine Modification of PTTG3P Contributes to Colorectal Cancer Proliferation via YAP1
Background: Long noncoding RNAs (lncRNAs) have emerged to have irreplaceable roles in the epigenetic regulation of cancer progression, but their biological functions in colorectal cancer (CRC) remain unclear. Methods: LncRNA expression profiles in CRC tissue and their normal counterpart were explored. Through gain and loss of function approaches, the role of lncRNA PTTG3P was validated in relevant CRC cells and subcutaneous tumor model. The correlations of PTTG3P expression with clinical outcomes were assessed. Results: PTTG3P was upregulated in CRC tissues and was closely correlated with unsatisfactory prognosis. PTTG3P facilitated glycolysis and proliferation, and the transcriptional regulator YAP1 was necessary for PTTG3P-induced proliferation. Mechanistically, the N6-methyladenosine (m6A) subunit METTL3 increased PTTG3P expression by influencing its stability, while insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) could identify PTTG3P m6A methylation status and bind to it. IGF2BP2 knockdown partly recovered PTTG3P expression induced by METTL3, indicating that METTL3-regulated PTTG3P expression depended on the presence of IGF2BP2. Finally, rescue assays validated the critical role of the METTL3/PTTG3P/YAP1 axis on CRC proliferation. Conclusions: PTTG3P is an independent prognostic biomarker for CRC. The METTL3/PTTG3P/YAP1 axis promotes the progression of CRC and is a promising treatment target.
- Open Access
- 6 July 2021
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (7)
Hypoxia-induced PTTG3P contributes to colorectal cancer glycolysis and M2 phenotype of macrophage
Long noncoding RNAs (lncRNAs) play critical factors in tumor progression and are ectopically expressed in malignant tumors. Until now, lncRNA pituitary tumor-transforming 3, pseudogene (PTTG3P) biological function in colorectal cancer (CRC) further needs to be clarified. qRT-PCR was used to measure the PTTG3P level and CCK-8, glucose uptake, lactate assay, adenosine triphosphate (ATP) assay, extracellular acidification rate (ECAR) assay, and xenograft mice model were adopted to evaluate the glycolysis and proliferation, and macrophage polarization were determined in CRC cells. Xenograft experiments were utilized to analyze tumor growth. Ectopic expression of PTTG3P was involved in CRC and related to dismal prognosis. Through gain- and loss-of-function approaches, PTTG3P enhanced cell proliferation and glycolysis through YAP1. Further, LDHA knockdown or glycolysis inhibitor (2-deoxyglucose (2-DG), 3-BG) recovered from PTTG3P-induced proliferation. And PTTG3P overexpression could facilitate M2 polarization of macrophages. Silenced PTTG3P decreased the level of inflammatory cytokines TNF-α, IL-1β and IL-6, and low PTTG3P expression related with CD8+ T, NK, and TFH cell infiltration. Besides, hypoxia-inducible factor-1α (HIF1A) could increase PTTG3P expression by binding to the PTTG3P promoter region. Hypoxia-induced PTTG3P contributes to glycolysis and M2 phenotype of macrophage, which proposes a novel approach for clinical treatment.
- 6 July 2021
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (7)
Open AccessHypoxia-induced PTTG3P contributes to colorectal cancer glycolysis and M2 phenotype of macrophage
Long noncoding RNAs (lncRNAs) play critical factors in tumor progression and are ectopically expressed in malignant tumors. Until now, lncRNA pituitary tumor-transforming 3, pseudogene (PTTG3P) biological function in colorectal cancer (CRC) further needs to be clarified. qRT-PCR was used to measure the PTTG3P level and CCK-8, glucose uptake, lactate assay, adenosine triphosphate (ATP) assay, extracellular acidification rate (ECAR) assay, and xenograft mice model were adopted to evaluate the glycolysis and proliferation, and macrophage polarization were determined in CRC cells. Xenograft experiments were utilized to analyze tumor growth. Ectopic expression of PTTG3P was involved in CRC and related to dismal prognosis. Through gain- and loss-of-function approaches, PTTG3P enhanced cell proliferation and glycolysis through YAP1. Further, LDHA knockdown or glycolysis inhibitor (2-deoxyglucose (2-DG), 3-BG) recovered from PTTG3P-induced proliferation. And PTTG3P overexpression could facilitate M2 polarization of macrophages. Silenced PTTG3P decreased the level of inflammatory cytokines TNF-α, IL-1β and IL-6, and low PTTG3P expression related with CD8+ T, NK, and TFH cell infiltration. Besides, hypoxia-inducible factor-1α (HIF1A) could increase PTTG3P expression by binding to the PTTG3P promoter region. Hypoxia-induced PTTG3P contributes to glycolysis and M2 phenotype of macrophage, which proposes a novel approach for clinical treatment.
- Open Access
- 15 June 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-16
TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner
Background: Ubiquitylation modification is one of the multiple post-transcriptional process to regulate cellular physiology, including cell signaling, cycle regulation, DNA repair and transcriptional regulation. Members of TRIM family proteins could be defined as E3 ubiquitin ligases as they contain a RING-finger domain, and alterations of TRIM proteins are involved into a broad range of diverse disorders including cancer. TRIM37 is a novel discovered E3 ubiquitin ligase and acts as a oncoprotein in multiple human neoplasms, however its biological role in RCC still remains elusive.Methods: RCC microarray chips and public datasets were screened to identify novel TRIMs member as TRIM37, which was dysregulated in RCC. Gain or loss of functional cancer cell models were constructed, and in vitro and in vivo assays were performed to elucidate its tumorigenic phenotypes. Interactive network analyses were utilized to define intrinsic mechanism.Results: We identified TRIM37 was upregulated in RCC tumors, and its aberrant function predicted aggressive neoplastic phenotypes, poorer survival endings. TRIM37 promoted RCC cells EMT and malignant progression via TGF-β1 signaling activation, as a consequence of directly mediated by ubiquitinating-H2A modifications.Conclusions: Our findings identified a previously unappreciated role of TRIM37 in RCC progression and prognostic prediction. Importantly, we declared a novel ubiquitination-dependent link between TRIM ubiquitin ligases and TGF-β1 signaling in regulating cancerous malignancies.
- 15 June 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-16
Open AccessTRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner
Background: Ubiquitylation modification is one of the multiple post-transcriptional process to regulate cellular physiology, including cell signaling, cycle regulation, DNA repair and transcriptional regulation. Members of TRIM family proteins could be defined as E3 ubiquitin ligases as they contain a RING-finger domain, and alterations of TRIM proteins are involved into a broad range of diverse disorders including cancer. TRIM37 is a novel discovered E3 ubiquitin ligase and acts as a oncoprotein in multiple human neoplasms, however its biological role in RCC still remains elusive.Methods: RCC microarray chips and public datasets were screened to identify novel TRIMs member as TRIM37, which was dysregulated in RCC. Gain or loss of functional cancer cell models were constructed, and in vitro and in vivo assays were performed to elucidate its tumorigenic phenotypes. Interactive network analyses were utilized to define intrinsic mechanism.Results: We identified TRIM37 was upregulated in RCC tumors, and its aberrant function predicted aggressive neoplastic phenotypes, poorer survival endings. TRIM37 promoted RCC cells EMT and malignant progression via TGF-β1 signaling activation, as a consequence of directly mediated by ubiquitinating-H2A modifications.Conclusions: Our findings identified a previously unappreciated role of TRIM37 in RCC progression and prognostic prediction. Importantly, we declared a novel ubiquitination-dependent link between TRIM ubiquitin ligases and TGF-β1 signaling in regulating cancerous malignancies.